RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TL;DR
Dr. Zamore's appointment enhances TransCode's RNA-targeted cancer therapy programs, giving a strategic advantage in cutting-edge treatment.
Dr. Zamore, a pioneer in RNA biology, joins TransCode's Scientific Advisory Board, advancing innovative RNA therapeutics for metastatic tumors.
Dr. Zamore's work at TransCode offers hope for improved cancer treatments, potentially leading to better outcomes for patients battling metastatic disease.
Joining TransCode, Dr. Zamore brings groundbreaking expertise in RNA research, expanding possibilities for cutting-edge cancer therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has strengthened its scientific leadership by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Zamore, a distinguished researcher in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings substantial expertise to the oncology-focused company's research efforts.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore is recognized for foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences underscores his significant contributions to the field of genetic research.
The appointment signals TransCode's commitment to advancing RNA-targeted cancer therapies. The company's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis.
Zamore's expertise could potentially accelerate TransCode's development of innovative RNA therapeutic approaches, particularly in addressing challenging genetic targets for cancer treatment. His involvement represents a strategic enhancement of the company's scientific capabilities and research potential.
Curated from InvestorBrandNetwork (IBN)
